Xeris Biopharma (XERS) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Portfolio overview and product performance

• Three main products: Gvoke (diabetes rescue), Recorlev (Cushing's/hypercortisolism), and Keveyis (PPP), with Gvoke and Recorlev as primary growth drivers.

• Gvoke leverages XeriSol technology for a ready-to-use glucagon, replacing older, less user-friendly kits.

• Recorlev targets cortisol synthesis, gaining adoption among endocrinologists for its direct mechanism and is driving significant revenue growth.

• Keveyis, despite generic competition, maintains strong brand loyalty due to support services and patient/physician preference.

• Recent partnership with ADA aims to increase awareness and compliance for Gvoke among the 15 million at-risk patients.

Commercial strategy and market dynamics

• Expanded sales force by 50% in Q3, accelerating patient referrals and starts, especially for Recorlev.

• Focus on shifting standard of care to standard of practice for Gvoke, emphasizing clinician and patient education.

• Entered a development agreement with Beta Bionics for pump-compatible glucagon, with formulation delivered and regulatory progress ongoing.

• U.S.-centric commercial focus, with international expansion pursued through partnerships; recently ended direct European Gvoke distribution.

• Ongoing confidential collaborations using XeriSol and XeriJect technologies, with public disclosure tied to material revenue impact.

Pipeline and innovation

• XP-8121, a once-weekly subcutaneous levothyroxine, addresses unmet needs for patients not normalized on oral therapy, targeting 20%+ of current users.

• XP-8121 leverages proprietary technology, with supportive PK data and ongoing FDA discussions; phase 3 trial planning underway with mid-year update expected.

• Physician feedback highlights significant interest due to challenges in managing oral therapy patients.

• Pipeline development is balanced with financial discipline and top-line growth.